Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-020687

PRESIDENT AND CEO sold 2,270 shares at $27.56 ($62,555)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Kintz Samuel · PRESIDENT AND CEO

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2024-07-31 Sale : show line 1 in the form 10b5-1 −2,270 $27.56 $62,555 1,061,255 I
Open-market sales · 2,270 sh · avg $27.56 · $62,555
Loading xslF345X05/form4-08022024_110802.xml…